A phase II study of gefitinib in combination with S-1 plus carboplatin as first-line triplet chemotherapy for patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e19095-e19095
Author(s):  
Akihiro Tamiya ◽  
Motohiro Tamiya ◽  
Takeshi Nakatani ◽  
Takayuki Shiroyama ◽  
Kanako Kitai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Phase Ii Study ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Epidermal Growth

Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond

2019 ◽  
Vol 14 (2) ◽  
pp. 120-128 ◽  
Author(s):  
Danilo Rocco ◽  
Ciro Battiloro ◽  
Luigi Della Gravara ◽  
Cesare Gridelli
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Activating Mutations ◽  
Epidermal Growth

Background:Lung cancer is the leading cause of cancer mortality, being responsible for more than 1.6 million deaths each year worldwide and non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancers; moreover, 10 to 15% of all NSCLCs harbor EGFR (epidermal growth factor receptor) activating mutations, being suitable for EGFR-Tyrosine Kinase Inhibitors (TKI) molecular targeted therapy. However, EGFR+ NSCLCs gain acquired resistance to these agents, representing one of the key challenges for modern precision oncology.Objective:herefore, this paper aims to provide an extensive state of the art review, alongside with hints about future perspectives.Conclusion:To date, in the light of the data from the FLAURA study, osimertinib represents the best first-line option in NSCLC patients with EGFR activating mutations; EGFR-TKI plus chemotherapy combination therapies, even though interesting, must still be considered investigational.

Sign in / Sign up

Export Citation Format

Share Document